Cited by 401BRCA gene mutations in cancerPancreatic and Hepatic Oncology ResearchGenetic factors in colorectal cancer

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma

Open access

Holter, Spring, Borgida, Ayelet, Dodd, Anna, Grant, Robert, Semotiuk, Kara, Hedley, David, Dhani, Neesha, Narod, Steven, Akbari, Mohammad, Moore, Malcolm, Gallinger, Steven·2015·Journal of Clinical Oncology

DOI 10.1200/jco.2014.59.7401

Open this paper in CoChat — free account Open PDF

Abstract

Purpose: The main purpose of this study was to determine the prevalence of pathogenic BRCA1 and BRCA2 mutations in a consecutively ascertained clinic-based cohort of patients with pancreatic ductal adenocarcinoma and describe the clinical and family history characteristics. Patients and Methods: Unselected, consecutive, incident patients with pancreatic ductal adenocarcinoma were recruited at a single cancer center over a 2-year period. Participants provided blood for DNA analysis and cancer family history, and cancer treatment records were reviewed. DNA from all patients was analyzed by Sanger sequencing and multiplex ligation-dependent probe amplification for germline variants in BRCA1 and BRCA2. Results: Three hundred six patients were eligible for analysis. Pathogenic germline BRCA mutations were identified in 14 patients (4.6%; 95% CI, 2.2% to 6.9%), including 11 patients with a BRCA2 mutation and three patients with a BRCA1 mutation. Having a cancer family history that met genetic testing criteria of the National Comprehensive Cancer Network or the Ontario Ministry of Health and Long-Term Care or self-reporting as Ashkenazi Jewish was significantly associated with BRCA mutation carrier status (P = .02, P < .001, and P = .05, respectively). However, the majority of the BRCA mutation–positive patients did not actually meet these genetic testing criteria. Conclusion: Pathogenic BRCA mutations were identified in 4.6% of a large cohort of clinic-based patients. Considering the implications for family members of BRCA carriers, and possibly tailored chemotherapeutic treatment of patients, our finding has implications for broader BRCA genetic testing for patients with pancreatic ductal adenocarcinoma.

Integrity signals

Registry

Crossref · 10.1200/jco.2014.59.7401

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.
Easton, D. F., Ford, D., & Bishop, D. T. (1995) · PubMed Central · Cited by 1,602
Cancer risks in BRCA2 mutation carriers.
Olsson, H. (1999) · Journal of the National Cancer Institute · doi:10.1093/jnci/91.15.1310 · Cited by 1,404
Cancer Incidence in BRCA1 mutation carriers.
Thompson, D., & Easton, D. (2002) · Journal of the National Cancer Institute · doi:10.1093/jnci/94.18.1358 · Cited by 1,231
Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas
Pennington, K. P., Walsh, T., Harrell, M. I., Lee, M. K., Pennil, C. C., Rendi, M. H., Thornton, A., Norquist, B. M., Casadei, S., Nord, A. S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2287 · Cited by 1,075
A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair
Ashworth, A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.0812 · Cited by 872
Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene
Jones, S., Hruban, R. H., Kamiyama, M., Borges, M., Zhang, X., Parsons, D. W., Lin, J. C.-H., Palmisano, E., Brune, K., Jaffee, E. M., et al. (2009) · Science · doi:10.1126/science.1171202 · Cited by 826
International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer
Canto, M. I., Harinck, F., Hruban, R. H., Offerhaus, G. J., Poley, J.-W., Kamel, I., Nio, Y., Schulick, R. S., Bassi, C., Kluijt, I., et al. (2013) · Gut · doi:10.1136/gutjnl-2012-303108 · Cited by 784
Population BRCA1 and BRCA2 Mutation Frequencies and Cancer Penetrances: A Kin–Cohort Study in Ontario, Canada
Risch, H. A., McLaughlin, J. R., Cole, D. E. C., Rosen, B. P., Bradley, L., Fan, I., Tang, J., Li, S., Zhang, S., Shaw, P. A., et al. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj465 · Cited by 678
Self-citation
Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas.
Goggins, M., Schutte, M. E. M., Lü, J., Moskaluk, C. A., Weinstein, C. L., Petersen, G. M., Yeo, C. J., Jackson, C. E., Lynch, H. T., Hruban, R. H., et al. (1996) · PubMed · Cited by 642

Flagged first, then by citations

Show all 39 references

Research works printed but not linked: 5

Lal G, 2000, Cancer Res, 60, 409
Tersmette AC, 2001, Clin Cancer Res, 7, 738
Murphy KM, 2002, Cancer Res, 62, 3789
Goggins M, 1996, Cancer Res, 56, 5360
Levy-Lahad E, 1997, Am J Hum Genet, 60, 1059

Sorted by citations

Items 301–400 of 401

Germline sequence analysis of RABL3 in a large series of pancreatic ductal adenocarcinoma patients reveals no evidence of deleterious variants
Roberts, N. J., Grant, R. C., Gallinger, S., Klein, A. P., & the Familial Pancreatic Cancer Genome Sequencing Project (2021) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22947 · Cited by 3
Self-citation
Targeting Advanced Pancreatic Ductal Adenocarcinoma: A Practical Overview
Citterio, C., Vecchia, S., Mordenti, P., Anselmi, E., Ratti, M., Guasconi, M., & Orlandi, E. (2025) · Gastroenterology Insights · doi:10.3390/gastroent16030026 · Cited by 2
KRAS-Wild Pancreatic Cancer—More Targets than Treatment Possibilities?
Krupa, K., Fudalej, M. M., Miski, H., Włoszek, E., Szymczak, M., Badowska-Kozakiewicz, A. M., Czerw, A. I., & Deptała, A. (2025) · Cancers · doi:10.3390/cancers17233769 · Cited by 2
SEOM-GETTHI clinical guideline for the practical management of molecular platforms (2021)
de la Haba-Rodríguez, J., Lloret, F. F., Salgado, M. Á. V., Oré-Arce, M., Cardeña-Gutiérrez, A., Jiménez, J. G.-D., Zambrano, C. B., Rodríguez-Alonso, R. M., López‐López, R., & Salas, N. R. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-022-02817-8 · Cited by 2
Adenocarcinomas ☆
Hartmann, D., & Friess, H. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-809633-8.06013-1 · Cited by 2
Pancreatic mixed acinar–neuroendocrine carcinoma in a patient with a germline BRCA2 mutation: a case report
Ikeda, M., Miura, S., Kume, K., Kikuta, K., Hamada, S., Takikawa, T., Nakagawa, K., Unno, M., Furukawa, T., & Masamune, A. (2022) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-022-01668-8 · Cited by 2
Clinical Updates for Gastrointestinal Malignancies
Laface, C., & Memeo, R. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13091424 · Cited by 2
Incidental germline findings during comprehensive genomic profiling of pancreatic and colorectal cancer: single-centre, molecular tumour board experience
Eid, M., Trizuljak, J., Taslerová, R., Gryc, M., Vlažný, J., Vilmanova, S., Jelinkova, M., Homolová, A., Tuček, Š., Hlavsa, J., et al. (2024) · Mutagenesis · doi:10.1093/mutage/geae014 · Cited by 2
Genome-Wide Analysis to Assess if Heavy Alcohol Consumption Modifies the Association between SNPs and Pancreatic Cancer Risk
Ni, Z., Kundu, P., McKean, D. F., Wheeler, W., Albanes, D., Andreotti, G., Antwi, S. O., Arslan, A. A., Bamlet, W. R., Freeman, L. E. B., et al. (2024) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-24-0096 · Cited by 2
Self-citation
Genetic determination of pancreatic cancer
Głuszek, S., & Kozieł, D. (2018) · Medical Studies · doi:10.5114/ms.2018.76879 · Cited by 2
A New Targeted Treatment for Patients with a Germline BRCA Mutation: Olaparib in Pancreatic Cancer
Verdaguer, H., Acosta, D., & Macarulla, T. M. (2020) · Future Oncology · doi:10.2217/fon-2020-0334 · Cited by 2
Genetic testing to guide screening for pancreatic ductal adenocarcinoma: Results of a microsimulation model
Peters, M. L. B., Eckel, A. L., Lietz, A., Seguin, C. L., Mueller, P. P., Hur, C., & Pandharipande, P. V. (2022) · Pancreatology · doi:10.1016/j.pan.2022.05.003 · Cited by 2
Targeted Therapies for Pancreatic Cancer
Lee, M. S., & Pant, S. (2023) · Springer eBooks · doi:10.1007/978-3-031-38623-7_5 · Cited by 2
Alteration of Transforming Growth Factor β Signaling Pathway Predicts Worse Prognosis in Pancreatic Ductal Adenocarcinoma
Mao, L., Li, A., Zhao, X., Hou, S., Lu, S., Mou, Y., Liu, X., Cai, S., Cao, D., & Tian, B. (2020) · Pancreas · doi:10.1097/mpa.0000000000001522 · Cited by 2
Report from the 21st Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Calgary, Alberta; 20–21 September 2019
Lee‐Ying, R. M., Ahmed, O., Ahmed, S., Ahmed, S., Bathe, O. F., Brunet, B., Dawson, L. A., Davies, J. M., Gordon, V., Hebbard, P. C., et al. (2021) · Current Oncology · doi:10.3390/curroncol28050310 · Cited by 2
Familial Pancreatic Cancer
Klein, A. P. (2018) · doi:10.1002/9781119188421.ch91 · Cited by 2
A chance in hopeless cancer: 5-year complete remission after oxaliplatin-based therapy in a patient with BRCA2 mutant metastatic pancreatic cancer
Yıldırım, H. Ç., İsmayılov, R., Akyıldız, A., Güven, D. C., Abdurrahimli, N., Dızdar, Ö., & Yalçın, Ş. (2022) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001486 · Cited by 1
Molecular Tissue Profiling in a Clinically Selected Pancreatic Cancer Cohort
Hegenberg, S., Germing, T., Schlageter, E., Ekmekçiu, I., Christmann, J., Tannapfel, A., & Reinacher‐Schick, A. (2025) · Oncology Research and Treatment · doi:10.1159/000543997 · Cited by 1
Characteristics of KRAS WT pancreatic adenocarcinomas: results of a large French multicentric cohort
Trystram, N., Cros, J. F., Blons, H., Garinet, S., Nicolle, R., Corre, D. L., Zhao, S. L., Biagi, J. J., Harlé, A., Conroy, T., et al. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251339939 · Cited by 1
Sequential platinum and PARP Inhibition enhances PD1 immunotherapy efficacy in murine Brca2 mutated pancreatic cancer
McVey, J. C., Wattenberg, M. M., Coho, H., Infante, K., Markowitz, K., Delman, D., Clendenin, C. J., Furth, E. E., Tondon, R., Stanger, B. Z., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-35423-7 · Cited by 1
FOLFIRINOX vs. Gemcitabine/Nab‐Paclitaxel for Pancreatic Cancer by BRCA2 and TMB Status: A Japanese C‐ CAT Database Study
Mizuno, K., Ishikawa, T., Ito, T., Takano, Y., Maeda, O., Kawashima, H., & Ando, Y. (2026) · Cancer Science · doi:10.1111/cas.70351 · Cited by 1
Chromatographic Method for Simultaneous Quantification of Gemcitabine and Olaparib Recovered from Isolated Pancreatic Tissue
Silva, M. T., Matos, B. N., Rego, M. O. A. C. Y. R. J. B. D. M., Gratieri, T., Cunha-Filho, M., & Gelfuso, G. M. (2026) · Chemistry · doi:10.3390/chemistry8050063 · Cited by 1
HRD Score: A Promising Biomarker for Genomic Instability Evaluation for Targeted Treatments Among Pancreatic Cancer Patients
Wang, X., Zhang, Q., Xu, Y., Miao, W., Tao, B., Jin, C., & Fu, D. (2026) · Technology in Cancer Research & Treatment · doi:10.1177/15330338261469099 · Cited by 1
Biweekly gemcitabine and low-dose cisplatin in the treatment of locally advanced or metastatic pancreatic cancer patients: a single institute experience
Lundberg, J., Reardon, J., Blazer, M. A., Phillips, G. S., & Bekaii‐Saab, T. (2015) · Medical Oncology · doi:10.1007/s12032-015-0720-x · Cited by 1
Cell Cycle Machinery and Its Alterations in Pancreatic Cancer
Kojima, Y., Maskey, R. S., & Machida, Y. (2018) · Springer eBooks · doi:10.1007/978-1-4939-7193-0_74 · Cited by 1
BRCA1 and BRCA2 Mutation in Pancreatic Cancer: Significance in Therapeutic Approach
Chakraborty, A. (2017) · Austin Journal of Gastroenterology · doi:10.26420/austinjgastroenterol.2017.1076 · Cited by 1
Hereditary Syndromes and Pancreatic Cancer
Pölsler, L., Claes, K., & Zschocke, J. (2021) · Springer eBooks · doi:10.1007/978-3-030-53786-9_3 · Cited by 1
Excision Repair Cross-Complementation Group 6 Gene Polymorphism Is Associated with the Response to FOLFIRINOX Chemotherapy in Asian Patients with Pancreatic Cancer
Choi, Y. H., Lim, Y., Ryu, J. K., Paik, W. H., Lee, S. H., Kim, Y., & Kim, J. H. (2021) · Cancers · doi:10.3390/cancers13061196 · Cited by 1
Pancreatic acinar cell carcinoma with neuroendocrine differentiation associated with BRCA2 mutation -a case report-
Yamashita, M., Kugiyama, T., Sumida, Y., Tanaka, T., YAMAZAKI, S., Takei, D., Hara, Y., Fukuda, A., Hisanaga, M., Wakata, K., et al. (2023) · Suizo · doi:10.2958/suizo.38.163 · Cited by 1
The Initial Journey of Patients with Metastatic Pancreatic Cancer (PaCTO Project): A Nationwide Survey among Portuguese Specialist Physicians
Barros, A. G., Mansinho, H., Couto, N., Teixeira, M. R., Tonin, F. S., Francisco, R., & Duarte‐Ramos, F. (2023) · GE Portuguese Journal of Gastroenterology · doi:10.1159/000533178 · Cited by 1
Clinical practice guidelines for interventional treatment of pancreatic cancer
Pourali, G., Donyadideh, G., Mehrabadi, S., Fiuji, H., Hassanian, S. M., Ferns, G. A., Khazaei, M., & Avan, A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-19142-8.00008-5 · Cited by 1
Olaparib not cost-effective as maintenance therapy for platinum-sensitive, BRCA1/2 germline-mutated metastatic pancreatic cancer
Mehra, T., Lupatsch, J. E., Koessler, T., Dedes, K. J., Siebenhüner, A. R., von Moos, R., WICKI, A. N., & Schwenkglenks, M. M. (2024) · PLoS ONE · doi:10.1371/journal.pone.0301271 · Cited by 1
Standards de chimiothérapie, perspectives et thérapies ciblées dans l’adénocarcinome du pancréas
Lambert, A., & Conroy, T. (2015) · ONCOLOGIE · doi:10.1007/s10269-015-2562-8 · Cited by 1
Long-term response to olaparib in a patient with metastatic pancreatic cancer associated with hereditary breast and ovarian cancer syndrome
Tsuneizumi, M., Terada, S., Usui, T., Yamaguchi, K., Hayami, R., & Matsunuma, R. (2022) · Oxford Medical Case Reports · doi:10.1093/omcr/omac124 · Cited by 1
Identification of a large intra-exonic deletion in BRCA2 exon 18 in a pancreatic ductal adenocarcinoma
Debbabi, I., Vacher, S., Neuzillet, C., Cros, J. F., Révillon, F., Petitalot, A., Turpin, A., Antonio, S., Girard, E., Dupain, C., et al. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221146132 · Cited by 1
BRCA mutational status shapes the stromal microenvironment of pancreatic cancer linking CLU + CAF expression with HSF1 signalingPreprint
Shaashua, L., Pevsner‐Fischer, M., Friedman, G., Levi-Galibov, O., Nandakumar, S., Nevo, R., Brown, L. E., Zhang, W., Stein, Y., Kim, H. S., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.18.456576 · Cited by 1
Inter- and intra-tumoral heterogeneity and dynamics of cancer-associated fibroblasts in pancreatic ductal adenocarcinoma
Neuzillet, C. (2018) · theses.fr (ABES) · doi:10.70675/71b3d021zb0eaz45a4z95a5zdb254dc5bde0 · Cited by 1
BRCA-Mutation: bei knapp 5 % der Adenokarzinome des Pankreas
Kreutzkamp, B. (2015) · Im Focus Onkologie · doi:10.1007/s15015-015-1993-9
Pancreatic Cancer: Background and Clinical Evidence
Burkhart, R. A., Rosati, L. M., & Herman, J. M. (2017) · Springer eBooks · doi:10.1007/978-3-319-43115-4_7
Synthetic Lethality: Achilles Heel in Select Patient Subpopulations
Teo, M. Y., & O'Reilly, E. M. (2017) · Springer eBooks · doi:10.1007/978-3-319-58256-6_14
Neue Ansätze in der Therapie des metastasierten Pankreaskarzinoms
Westphalen, C. B., & Heinemann, V. (2018) · Im Focus Onkologie · doi:10.1007/s15015-018-4103-y
Immune Checkpoint Inhibitors in Gastrointestinal Malignancies
Fountzilas, C. K., Lee, S. S., Iyer, R. V., & Boland, P. M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-54948-6.00004-4
GERMINAL MUTATIONS IN HOMOLOGOUS RECOMBINATION GENES IN A POPULATION OF PATIENTS WITH PANCREATIC CANCER: A SINGLE CENTRE EXPERIENCE
Покатаев, И. А., Попова, А. С., Abramov, I. S., Emelyanova, M., Nasedkina, T. V., Lyubchenko, L. N., Bazin, L. S., Артамонова, Е. В., Fedyanin, M. Y., Menshikova, S. F., et al. (2018) · Malignant tumours · doi:10.18027/2224-5057-2018-8-3-5-12
Survival, Treatment Patterns, and Identifying Predictors of Receipt of Adjuvant Therapy and Survival for Curative-intent Pancreatic Adenocarcinoma: A Population-based Analysis
Kagedan, D. J. (2016) · TSpace (University of Toronto)
L’étude POLO
Hammel, P. R. (2019) · Bulletin du Cancer · doi:10.1016/j.bulcan.2019.07.003
Germline BRCA2 mutation pancreatic adenocarcinoma
Chen, M., & Chen, W. (2020) · Journal of Cancer Research and Practice · doi:10.4103/jcrp.jcrp_20_19
Identification of candidate genes predisposing to familial colorectal cancer by germline whole exome sequencing
Lung, M. S. (2019) · Minerva Access (University of Melbourne)
Standard-verändernde Neuigkeiten aus der internistischen Onkologie
Zschäbitz, S., Busch, E., Woydack, L., & Jäger, D. (2020) · Der Klinikarzt · doi:10.1055/a-1278-5795
Chemotherapy for Advanced Pancreatic Cancer: Available Drugs, Mechanisms and Toxicity
Nagy, B. M., Lamarca, Á., McNamara, M. G., Hubner, R. A., & Valle, J. W. (2021) · Springer eBooks · doi:10.1007/978-3-030-53786-9_44
Cellular immunotherapy of pancreatic ductal adenocarcinoma: Discovery and evaluation of novel target candidates
Schäfer, D. (2021) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-8485
Pathologie und molekulare Marker
Tannapfel, A., & Munding, J. B. (2020) · Im Focus Onkologie · doi:10.1007/s15015-020-2350-1
Tumorrisikosyndrome: Erkennen - Untersuchen - Betreuen
Berking, A.-C., & Bergmann, A. K. (2021) · InFo Hämatologie + Onkologie · doi:10.1007/s15004-021-8651-5
Identification of women at risk for hereditary breast and ovarian cancer in a sample of 1000 Slovenian women: a comparison of guidelines
Kotnik, U., Peterlin, B., & Lovrečić, L. (2021) · BMC Cancer · doi:10.1186/s12885-021-08400-8
Biomarkers for Pancreatic Cancer and Cholangiocarcinoma
Kishikawa, T. (2021) · Springer eBooks · doi:10.1007/978-981-16-2870-2_3
Prognostic Significance of Disease Control at 12 Weeks in Patients With Advanced Pancreatic Cancer Receiving FOLFIRINOX as First-line Chemotherapy
Batra, A., Tang, P. A., & Cheung, W. Y. (2021) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000856
Avancées dans la prise en charge de l’adénocarcinome canalaire pancréatique
O'Kane, G. M., Ladak, F., & Gallinger, S. (2021) · Canadian Medical Association Journal · doi:10.1503/cmaj.201450-f · Cited by 1
Self-citation
Immune Landscape of Pancreas Ductal Adenocarcinoma: Current Therapeutic Strategies and Future Perspective
Zheng-Lin, B., & O'Reilly, E. M. (2021) · Cancer immunotherapy · doi:10.1007/13905_2021_8
Application of Text Mining Technologies Based on Indexing Model & Public Databases
Fu, X. (2021) · IEEE International Conference on Electronic Technology, Communication and Information (ICETCI) · doi:10.1109/icetci53161.2021.9563523
Stellungnahme zur Nutzenbewertung Olaparib (neues Anwendungsgebiet, Pankreaskarzinom, Erhaltungstherapie)
(2021) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1484-8161
The Poly(ADP-ribose) polymerase inhibitors in pancreatic cancer
Zubik, K., Talaśka, J., Sigorski, D., & Nawrocki, S. (2022) · Nowotwory Journal of Oncology · doi:10.5603/njo.2022.0004
Pathologische Aufbereitung beim duktalen Adenokarzinom des Pankreas – was gibt es Neues?
Munding, J. B., & Tannapfel, A. (2022) · Der Chirurg · doi:10.1007/s00104-022-01615-w
Familial Pancreatic Cancer
Roberts, N. J., & Wood, L. D. (2021) · Springer eBooks · doi:10.1007/978-3-030-53786-9_4
Cell Cycle Machinery and Its Alterations in Pancreatic Cancer
Kojima, Y., Maskey, R. S., & Machida, Y. (2017) · Springer eBooks · doi:10.1007/978-1-4939-6631-8_74-1
Circulating tumor DNA tracking in patients with pancreatic cancer using next-generation sequencing
Herreros‐Villanueva, M., Bujanda, L., Ruiz-Rebollo, L., Torremocha, R., Ramos, R., Martín, R., & Artigas, M. C. (2022) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2022.10.001
Germline Testing for Individuals with Pancreatic Adenocarcinoma and Novel Genetic Risk Factors
Chittenden, A. B., Haraldsdóttir, S., Chen, E., & Nissim, S. (2022) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2022.07.008
Management of Locally Advanced/Metastatic Disease: Medical Oncology
Mizrahi, J. D., & Wolff, R. A. (2022) · Springer eBooks · doi:10.1007/978-3-031-05724-3_9
Ductal Adenocarcinoma and Pancreatic Intraepithelial Neoplasia
(2023) · American Registry of PathologyArlington, Virginia eBooks · doi:10.55418/9781933477275-07
Complete Pathological Response to Platinum-Based Neoadjuvant Chemotherapy in BRCA2-Associated Locally Advanced Pancreatic Cancer: A Case Report and Literature Review
Asiri, M. S., Dabaliz, A., Almutairi, M., Almahbub, A., Alharbi, M., Almeman, S., Alshieban, S., Alotaibi, T. F., & Algarni, M. (2023) · Cureus · doi:10.7759/cureus.43261
Therapy for Metastatic Pancreatic Cancer
Musher, B., & Zhu, H. (2023) · Springer eBooks · doi:10.1007/978-3-031-38623-7_4
Supplementary Table S1 from The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib
Brown, T. J., Yablonovitch, A. L., Till, J. E., Yen, J. L., Kiedrowski, L. A., Hood, R., O’Hara, M. H., Teitelbaum, U. R., Karasic, T. B., Schneider, C. J., et al. (2023) · doi:10.1158/1078-0432.24825876.v1
Supplementary Table S1 from The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib
Brown, T. J., Yablonovitch, A. L., Till, J. E., Yen, J. L., Kiedrowski, L. A., Hood, R., O’Hara, M. H., Teitelbaum, U. R., Karasic, T. B., Schneider, C. J., et al. (2023) · doi:10.1158/1078-0432.24825876
Clinical significance of germline mutations in BRCA1/2 gene in pancreatic ductal adenocarcinoma (literature review)
Евгеньевич, М. В., Павловский, А. В., Popov, S. A., Гранов, Д. А., Turlak, A. S., & Рубенович, А. Г. (2024) · Medical alphabet · doi:10.33667/2078-5631-2023-36-7-12
The Revolution in Germline DNA Testing: Actionable Takeaways from the 2023 Precision Oncology Summit
Abuali, I. A., Abrams, H. R., Khan, A. M., Riaño, I., Münster, P. N., Yadav, S., & Dubard-Gault, M. E. (2024) · International Journal of Cancer Care and Delivery · doi:10.53876/001c.94045
Additional file 3 of Clinical characteristics and prognostic implications of BRCA-associated tumors in males: a pan-tumor survey
Sun, P., Li, Y., Chao, X., Li, J., Luo, R., Li, M., & He, J. (2020) · Figshare · doi:10.6084/m9.figshare.13093975
Additional file 4 of Clinical characteristics and prognostic implications of BRCA-associated tumors in males: a pan-tumor survey
Sun, P., Li, Y., Chao, X., Li, J., Luo, R., Li, M., & He, J. (2020) · Figshare · doi:10.6084/m9.figshare.13093978
Analysis of the occurrence of germline mutations BRCA1\2, PALB2, CHEK2, NBN in patients with pancreatic malignancies. Single-center cohort non-randomized retrospective study
Moiseenko, V., Карданова, И. Г., Pavlovsky, A. V., Рубенович, А. Г., & Гранов, Д. А. (2024) · Perm Medical Journal · doi:10.17816/pmj41233-41
Novel Therapies in Advanced Pancreatic Cancer: A Peak Beyond the Realms of Gene Targeting
Dave, P., Beriwala, V., Parikh, C., Uddin, A., Dayala, H., Patel, R. H., Chirumamilla, P. C., & Winer, A. (2025) · Cureus · doi:10.7759/cureus.89054
Continuous response to maintenance fuzuloparib for germline BRCA2- mutated metastatic pancreatic adenocarcinoma: a case report and literature review
Zhang, C., Zhang, P., Cheng, K., & Cao, D. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1656670
Diagnosis and treatment strategies for hereditary pancreatic cancer syndrome
Matsubayashi, H., Morizane, C., Kanai, M., Kiyozumi, Y., & Kitano, M. (2025) · International Journal of Clinical Oncology · doi:10.1007/s10147-025-02905-z
Targeted and immunotherapy strategies in pancreatic ductal adenocarcinoma: Recent developments and insights
Xie, C., Ke, J., & Liu, F. (2025) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2025.12.008 · Cited by 1
Additional file 1 of The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanced pancreatic ductal adenocarcinoma
Shui, L., Li, X., Peng, Y., Tian, J., Li, S., He, D., Li, A., Tian, B., Li, M., Gao, H., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14956007
Additional file 1 of DNA sequencing of anatomy lab cadavers to provide hands-on precision medicine introduction to medical students
Anandakrishnan, R., Carpenetti, T. L., Samuel, P., Wasko, B., Johnson, C., Smith, C., Kim, J., Michalak, P., Kang, L., Kinney, N., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13245946
Additional file 1 of Evaluation of inherited germline mutations in cancer susceptibility genes among pancreatic cancer patients: a single-center study
Tavano, F., Gioffreda, D., Fontana, A., Palmieri, O., Gentile, A., Latiano, T., Latiano, A., Latiano, T. P., Scaramuzzi, M., Maiello, E., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26564961
Additional file 1 of Clinical characteristics and prognostic implications of BRCA-associated tumors in males: a pan-tumor survey
Sun, P., Li, Y., Chao, X., Li, J., Luo, R., Li, M., & He, J. (2020) · Figshare · doi:10.6084/m9.figshare.13093969
Additional file 2 of Evaluation of inherited germline mutations in cancer susceptibility genes among pancreatic cancer patients: a single-center study
Tavano, F., Gioffreda, D., Fontana, A., Palmieri, O., Gentile, A., Latiano, T., Latiano, A., Latiano, T. P., Scaramuzzi, M., Maiello, E., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26564964
Additional file 1 of Identification of women at risk for hereditary breast and ovarian cancer in a sample of 1000 Slovenian women: a comparison of guidelines
Kotnik, U., Peterlin, B., & Lovrečić, L. (2021) · Figshare · doi:10.6084/m9.figshare.14728499
Additional file 2 of Clinical characteristics and prognostic implications of BRCA-associated tumors in males: a pan-tumor survey
Sun, P., Li, Y., Chao, X., Li, J., Luo, R., Li, M., & He, J. (2020) · Figshare · doi:10.6084/m9.figshare.13093972
Oligometastasierung im Gastrointestinaltrakt
Schleußner, N., Mönig, S., Gebauer, F., van Hillegersberg, R., Bruns, C. J., & Schmidt, T. (2026) · Die Chirurgie · doi:10.1007/s00104-025-02423-8
Third-line platinum-based chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma
Lan, C.-C., Chang, C.-Y., Chiu, T., Hung, C., Yeh, K., Lu, C., Chen, Y., Chen, J., Hung, Y., & Chou, W. (2026) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2026.01.057
Endoscopic ultrasound-guided tissue acquisition for comprehensive genomic profiling
Okuno, N., & Hara, K. (2026) · Choonpa Igaku · doi:10.3179/jjmu.jjmu.r.269
Système de connaissance expert dédié à la recherche translationnelle dans les maladies rares
Raï, G. (2016) · theses.fr (ABES) · doi:10.70675/68a9bbc4zb13cz4339z8dc0z6ef7dd8950f4
Apport de l'ADN circulant tumoral dans les cancers digestifs
Evrard, C. (2022) · theses.fr (ABES) · doi:10.70675/e887f785zd2daz4c33za83fzd8d4cd2f9935
Metachronous Colorectal Carcinomas and Pancreatic Metastasis in Clinically Suspected Lynch Syndrome: An 18-Year Oncologic Course
Jikurashvili, M., Narimanishvili, G., Gotsadze, I., Mariamidze, A., Chechelashvili, D., Gendzekhadze, M., Matcharashvili, S., Datunashvili, G., & Tchokhuri, S. (2026) · Cureus · doi:10.7759/cureus.109954
BRCA1/2 Reversion Mutations and Cancer Therapy Resistance
Qi, W., Yang, G., Zhang, Y., Han, L., Mayo, K. H., Zeng, X., & Mo, J. (2026) · Biology · doi:10.3390/biology15110866 · Cited by 1
Niraparib in pancreatic cancer with germline or somatic DNA damage repair (DDR) gene alterations (BRCA and beyond): a phase II study (NIRA-PANC)
Kasi, A., Al-Rajabi, R. M. T., Baranda, J. C., Saeed, A., Dai, J., Chalise, P., Weir, S. J., Sear, B., Carroll, E., Bradbury, S., et al. (2026) · The Oncologist · doi:10.1093/oncolo/oyag225
An integrative mutational and network analysis of pancreatic cancer reveals key genes, and signalling pathways
Manjunath, G. K., Kanchi, L. P., Dakal, T. C., Beura, A., & Kumar, A. (2026) · Functional & Integrative Genomics · doi:10.1007/s10142-026-01921-0
Genetic polymorphisms of DNA repair pathways in pancreatic cancer progression and treatment
Saraf, F., Purohit, M. R., Lakshmisundaram, R., Verma, H. K., & Bhaskar, L. V. K. S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-43976-6.00017-x
DNA damage response inhibitors in pancreatic cancer: progress and challenges
Wu, Y., Li, W., & Wu, M. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1838580
SEOM‑GETTHI clinical guideline for the practical management of molecular platforms (update 2026)
Salas, N. R., de la Haba-Rodríguez, J., Lloret, F. F., Salgado, M. Á. V., Oré-Arce, M., Cardeña-Gutiérrez, A., Zambrano, C. B., Rodríguez-Alonso, R. M., López‐López, R., & Jiménez, J. G.-D. (2026) · Clinical & Translational Oncology · doi:10.1007/s12094-026-04520-4 · Cited by 1
Gene therapy as an upcoming technique in the treatment of cancer: A cellular solution to a cellular problem
Bedada, A. T., & Genet, S. (2026) · Molecular Therapy Oncology · doi:10.1016/j.omton.2026.201352

Authors: Holter, S., Borgida, A., Dodd, A., Grant, R., Semotiuk, K., Hedley, D., Dhani, N., Narod, S., Akbari, M., Moore, M., & Gallinger, S.
Affiliations: Mount Sinai Hospital (CA)
Spring Holter, Ayelet Borgida, Robert Grant, Kara Semotiuk, and Steven Gallinger, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital; Anna Dodd, David Hedley, Neesha Dhani, Malcolm Moore, and Steven Gallinger, McCain Pancreatic Cancer Centre, University Health Network; and Steven Narod and Mohammad Akbari, Women's College Research Institute, Toronto, Ontario, Canada.
ORCID: Borgida, Ayelet
Dodd, Anna
Grant, Robert
Semotiuk, Kara
Hedley, David
Dhani, Neesha
Narod, Steven
Akbari, Mohammad
Moore, Malcolm
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2015-10-01
Volume: 33
Issue: 28
Pages: 3124-3129
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2014.59.7401
OpenAlex: W2161479848
Cited by: 398
References: 39
Citations by year: 2026: 18 · 2025: 19 · 2024: 23 · 2023: 40 · 2022: 40 · 2021: 71 · 2020: 50 · 2019: 27 · 2018: 42 · 2017: 30 · 2016: 26 · 2015: 12
FWCI: 25.18
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Funders: Canadian Cancer Society Research Institute
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Keywords: germline BRCA1 mutation, germline BRCA2 mutation, pancreatic ductal adenocarcinoma, family history of cancer, Ashkenazi Jewish ancestry, hereditary cancer predisposition
MeSH terms: Adult, Aged, Aged, 80 and over, DNA Mutational Analysis, Female, Gene Frequency, Humans, Jews, Male, Middle Aged, Ontario, Pancreatic Neoplasms, Pedigree, Phenotype, Prognosis, Prospective Studies, Risk Factors, Incidence, Germ-Line Mutation, BRCA1 Protein, Genetic Predisposition to Disease, Carcinoma, Pancreatic Ductal, BRCA2 Protein, Heredity, Multiplex Polymerase Chain Reaction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks